What Sticta Biologicals does

Sticta Biologicals is a private Chilean biotech startup headquartered at Centro de Innovación UC in Santiago, founded in 2021, that develops yeast-derived recombinant proteins and metabolites via precision fermentation for the cell-based meat, biopharmaceutical, and agriculture industries. The company's core technology stack combines protein engineering (AI-driven plus rational design), cellular engineering (proteome-constrained genome-scale models), and a biological platform that transforms microorganisms to produce high-value compounds cost-effectively, replacing traditional chemical and resource-heavy farming processes. Its commercial product portfolio includes Smart Insulin — described as the first insulin designed for cell culture applications, offering 10X lower cost versus conventional insulin and thermostable properties that eliminate cold chain logistics — and Smart Transferrin, a customized recombinant transferrin for bovine, porcine, and avian cells currently in development.

Sticta generates revenue through B2B sales of recombinant proteins, growth factors, and antimicrobial peptides to enterprise customers in cultivated meat, biopharma, and agriculture, with a go-to-motion built on direct engagement, R&D sample distribution, and a network of ecosystem partners including ProVeg, the Good Food Institute, Merken Biotech, and Chilean innovation agencies (CORFO, ANID, Dictuc). The company has disclosed one funding round of $137,467 from the ProVeg Incubator in April 2023, supports a 1–10 person core team augmented by specialized R&D personnel, and is led by CEO and co-founder Andrés Ariztía (former ADAMA LatAm R&D and Biosolutions leader) and co-founder Eduardo Agosin, PhD (35+ years in precision fermentation research and three prior food/beverage startups).

Name

Sticta Biologicals

Legal name

Sticta Biologicals

Website

https://sticta.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Sticta Biologicals is a Chilean precision fermentation startup producing yeast-derived recombinant proteins — including Smart Insulin and Smart Transferrin — for cultivated meat, biopharmaceutical, and agriculture customers, using AI-driven protein engineering to deliver cost-effective, thermostable alternatives to conventional cell culture inputs.

Ownership category

akta.pro rank

Product category

Precision Fermentation / Recombinant Proteins

NAICS

Food Manufacturing (311)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Fermentation-Derived Proteins (Precision Fermentation, Biomass Fermentation) (AFAJAHAH)

akta.pro secondary industries

Specialty & Novel Proteins (Single-Cell Protein, Cell-Cultured/Animal-Free Proteins) (AFAJAHAL), Proteins & Functional Nutrition Ingredients (Plant/Animal Proteins, Collagen, Amino Acids) (CRADAOAJ)

Keywords

• Precision fermentation proteins
• Recombinant insulin production
• Cell culture growth factors
• Cultivated meat inputs
• Yeast-based biomanufacturing

Headquarters

HQ city

Santiago

HQ country

Chile

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Recombinant Protein Sales: Sale of biosolutions including recombinant proteins, growth factors, and antimicrobial peptides produced through precision fermentation for B2B customers in cell culture and agriculture industries

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Sticta Biologicals produces and sells yeast-derived recombinant proteins, growth factors, and antimicrobial peptides via precision fermentation for B2B customers in cell culture, cultivated meat, biopharmaceuticals, and agriculture. Its named commercial products are Smart Insulin (a single-chain insulin for serum-free cell culture media, 10X cheaper and thermostable versus conventional insulin) and Smart Transferrin (bovine, porcine, and avian recombinant transferrins for serum-free media).

Product overview

Sticta Biologicals operates as a precision fermentation platform company offering two named recombinant protein products (Smart Insulin and Smart Transferrin) for the cell culture and agriculture industries. The platform encompasses six core capabilities (Protein Engineering, Cellular Engineering, Biological Platform, Product Development, Laboratory Scale, and Commercial Scale) that work together to accelerate the path from biosynthesis to commercialization, enabling cost-effective production of proteins and metabolites for cultivated meat, biopharmaceuticals, and agriculture sectors.

Differentiator

Problem solved

Functional benefit

Products and services

• Smart Insulin
• Smart Transferrin

Quantifiable outcome

• 10X lower cost compared to conventional insulin
• +1 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered minor.

• ProVegminorStrategic or Co-development PartnerOrganization supporting innovation and sustainability in food systems. Sticta works alongside ProVeg as part of their network of organizations committed to advancing biotechnology for sustainable food production.
• Merken BiotechminorStrategic or Co-development PartnerBiotechnology company partner collaborating in the network of organizations supporting Sticta's commitment to innovation and sustainability in biotechnology solutions.
• Good Food Institute (GFI)minorStrategic or Co-development PartnerNon-profit organization accelerating alternatives to conventional animal agriculture. Sticta collaborates with GFI as part of their network advancing alternative protein and fermentation technologies.
• CORFOminorOthersChilean Economic Development Agency providing support to companies advancing biotechnology and innovation in Chile.
• DictucminorOthersChilean technical and consulting organization affiliated with Pontifical Catholic University of Chile, supporting innovation and technology development.
• ANIDminorOthersChilean National Research and Development Agency supporting scientific and technological advancement in biotechnology sector.
• AmarenaminorOthersOrganization supporting startup and science-based ventures, part of Sticta's collaborative network.

Recent moves6 records

Expansion highlights6 records

Direct peers

• Biftek: Direct peer: Biftek produces recombinant growth factors (including insulin and transferrin) for the cultivated meat industry using precision fermentation, mirroring Sticta's core product strategy targeting cell culture media costs.
• BioBetter: BioBetter develops plant-based production of growth factors and complex proteins for cultivated meat, a closely adjacent approach to Sticta's yeast-based precision fermentation platform serving the same cultivated meat customers.
• Perfect Day: Perfect Day uses precision fermentation to produce animal-free dairy proteins (e.g., whey), making it a closely comparable precision fermentation CPG/biotech business targeting B2B food customers with cost-driven value propositions.
• The EVERY Company (formerly Clara Foods): The EVERY Company produces animal-free proteins (ovalbumin, etc.) via precision fermentation for food and beverage customers, comparable in platform technology and B2B ingredient go-to-market to Sticta's yeast-based protein platform.
• Solar Foods: Solar Foods uses precision fermentation (gas fermentation) to produce single-cell protein Solein for food applications, a comparable fermentation-derived protein ingredient play targeting food and feed markets.

Broad incumbents

• Ginkgo Bioworks: Ginkgo Bioworks is a large, established cell engineering and fermentation platform serving food, agriculture, and biopharma — overlapping with Sticta's protein engineering and biosolutions GTM, but at far greater scale and breadth.
• Novonesis (Novozymes): Novonesis is a global enzyme and microbial protein producer with established fermentation infrastructure across food, agriculture, and biopharma — a broad incumbent competitor with overlapping biosolutions capabilities to Sticta's protein and metabolite platform.

Emerging players

• Cauldron Molecules: Cauldron operates precision fermentation facilities at scale for alt-protein producers, comparable in business model (fermentation-as-a-service and ingredient production) to Sticta's commercial scale capability.
• Culture Biosciences: Culture Biosciences offers cloud-based fermentation R&D services and bioreactor capacity for biotech and alt-protein companies, overlapping with Sticta's laboratory-to-commercial scale fermentation capabilities.

Regional players

• Merken Biotech: Chile/Latin America-based biotechnology partner in Sticta's network, pursuing fermentation-based biosolutions with overlapping regional ecosystem and customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks1 record

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/sticta

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sticta Biologicals